<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474861</url>
  </required_header>
  <id_info>
    <org_study_id>CVD20180401002</org_study_id>
    <nct_id>NCT03474861</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Gastrointestinal Cancer</brief_title>
  <official_title>A Combination Study to Evaluate the Safety and Efficacy of an Anticancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Gastrointestinal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou Converd Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Hospital of Jia Xing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangzhou Converd Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study to evaluate the safety and efficacy of an anticancer medication
      (A01) combined with immune cells (IC01) in subjects with advanced Gastrointestinal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed.</measure>
    <time_frame>Day 0 to 4 months after the end of the trial</time_frame>
    <description>Incidence and duration of all the adverse events will be recorded. The severity of adverse events will be evaluated according to NCI-CTCAE v4.03 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response of the treatment in patients with advanced gastrointestinal cancer.</measure>
    <time_frame>Before treatment and Day 28 to 4 months after the end of the treatment</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) from the NCI will be used for assessment of radiographic response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be given combination therapy which consists of an anticancer medication (A01) and immune cells (IC01).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anticancer medication A01; immune cells IC01</intervention_name>
    <description>The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.
The subjects will be observed for any side effects during this time and all the adverse events will be recorded.</description>
    <arm_group_label>Combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent form must be obtained prior to any research procedures;

          2. Age: 18 Years to 70 Years;

          3. The patient's biological parent or child whose age ≥18 years voluntarily donates
             peripheral blood (200 ml) for the treatment, and who signs the informed consent form
             independently;

          4. Histologically confirmed diagnosis of gastrointestinal cancer;

          5. Patients who have received at least one standard treatment (surgery, chemotherapy,
             radiotherapy, or targeted therapy) or refuse to receive standard treatments;

          6. Karnofsky Performance Status (KPS) score ≥ 70

          7. Expected survival ≥ 3 months

          8. Adequate organ function defined as: ANC≥3.5×10^9/L, PLT≥50×10^9/L, ALB≥25g/L,
             AST≤2.5×ULN, ALT≤2.5×ULN, TBIL≤1.5×ULN

          9. If a subject is a female of childbearing potential, she must have a negative urine
             pregnancy test result.

        Exclusion Criteria:

          1. Patients who received chemotherapy, large-field radiotherapy or participated in other
             studies of anti-tumor therapy within 2 weeks before enrollment;

          2. Patients who have not recovered from adverse reactions related to above-mentioned
             procedures;

          3. Patients with two types of primary solid tumors;

          4. Patients with brain metastases or bone metastases;

          5. Patients with poorly controlled hypertension (systolic blood pressure &gt; 160 mmHg
             and/or diastolic blood pressure &gt; 90 mmHg), or cardiovascular and cerebrovascular
             diseases with clinical significance, such as cerebrovascular accident (within 6 months
             before signing informed consent), myocardial infarction (within 6 months before
             signing informed consent), unstable angina, congestive heart failure (New York Heart
             Association Class II or above), or severe arrhythmia which can't be controlled with
             drugs or have potential impact on treatment;

          6. Patients with other serious organic diseases or mental disorders;

          7. Patients with systemic or active infection;

          8. Patients with positive HIV test result;

          9. Patients who have received an organ transplant;

         10. Patients who are breastfeeding or pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Chen, PhD</last_name>
    <phone>+86 18005817715</phone>
    <email>chenlin@converd.com.cn</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

